References
Alexander, D. D., Mink, P. J., Adami, H.-O., Cole, P., Mandel, J. S., Oken, M. M., & Trichopoulos, D.
(2007). Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer, 120(S12), 40–61. https://doi.org/10.1002/ijc.22718
Amare, K. P., Nikalje Khasnis, S., Hande, P., Lele, H., Wable, N., Kaskar, S., Nikam Gujar, N., Gardi, N., Prabhudesai, A., Todi, K., Waghole, R., & Roy, P. (2022). Cytogenetic abnormalities in multiple myeloma: Incidence, prognostic significance, and geographic heterogeneity in Indian and Western populations. Cytogenetic and Genome Research, 162(10), 529–540.
https://doi.org/10.1159/000529191
Andriandi, & Kamal, A. F. (2019). Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. Annals of Medicine and Surgery, 41, 11–15. https://doi.org/10.1016/j.amsu.2019.03.011
Arsham, M. S., Barch, M. J., & Lawce, H. J. (2017). The AGT Cytogenetics Laboratory manual. The Association of Genetic Technologists. https://doi.org/10.1002/9781119061199
Bang, S.-M., Kim, Y. R., Cho, H. I., Chi, H. S., Seo, E.-J., Park, C. J., Yoo, S. J., Kim, H. C., Chun, H. G., Min, H. C., Oh, B. R., Kim, T. Y., Lee, J. H., & Lee, D. S. (2006). Identification of 13Q deletion, trisomy 1Q, and igh rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genetics and Cytogenetics, 168(2), 124–132.
https://doi.org/10.1016/j.cancergencyto.2006.02.015
Bergsagel, P. L., & Kuehl, W. M. (2001). Chromosome translocations in multiple myeloma. Oncogene, 20(40), 5611–5622. https://doi.org/10.1038/sj.onc.1204641
Bianchi, G., & Munshi, N. C. (2015). Pathogenesis beyond the cancer clone(s) in multiple myeloma.
Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C.
P., Thanendrarajan, S., Zangari, M., Facon, T., Dumontet, C., Barlogie, B., Arbini, A., Rustad, E.
H., Maura, F., Landgren, O., Zhan, F., van Rhee, F., … Walker, B. A. (2021). The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Nature Communications, 12(1). https://doi.org/10.1038/s41467-020-20524-2
Bridge, J. A. (2008). Advantages and limitations of cytogenetic, molecular cytogenetic, and molecular diagnostic testing in mesenchymal neoplasms. Journal of Orthopaedic Science, 13(3), 273–282.
https://doi.org/10.1007/s00776-007-1215-1
Chesi, M., & Bergsagel, P. L. (2015). Advances in the pathogenesis and diagnosis of multiple myeloma.
International Journal of Laboratory Hematology, 37(S1), 108–114.
https://doi.org/10.1111/ijlh.12360
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., ... & Mey, U.
(2021). Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(3), 309-322. https://doi.org/10.1016/j.annonc.2020.11.014
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2018). Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. International Journal of Cancer, 144(8), 1941–1953.
https://doi.org/10.1002/ijc.31937
Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020). Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells, 9(2), 287.
https://doi.org/10.3390/cells9020287
Gao, X., Li, C., Zhang, R., Yang, R., Qu, X., Qiu, H., Xu, J., Lu, H., Li, J., &; Chen, L. (2011). Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. Medical Oncology, 29(3), 2200–2206. https://doi.org/10.1007/s12032-011-9988-7
GLOBOCAN. (2020). Indonesia - International Agency for Research on Cancer. International Agency for
Research on Cancer.
https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
Govindasamy, P., Pandurangan, P., Tarigopula, A., Mani, R., & R Samuel, C. (2019). Cytogenetic abnormalities in multiple myeloma patients at a tertiary healthcare center in India. Asian Pacific Journal of Cancer Prevention, 20(1), 235–241.
https://doi.org/10.31557/apjcp.2019.20.1.235
Gu, J., Smith, J. L., & Dowling, P. K. (2016). Fluorescence in situ hybridization probe validation for
clinical use. Methods in Molecular Biology, 101–118.
https://doi.org/10.1007/978-1-4939-6703-2_10
Hameed, A., Ali, J., Munawar, K., Arshad, F., Badar, F., & Siddiqui, N. (2018). Characteristics and outcomes of patients with multiple myeloma : Data from a developing country. Medical Journal of The Islamic Republic of Iran, 32(1), 1–5. https://doi.org/10.14196/mjiri.32.1
Hartmann, L., Biggerstaff, J. S., Chapman, D. B., Scott, J. M., Johnson, K. R., Ghirardelli, K. M., Fritschle, W. K., Martinez, D. L., Bennington, R. K., de Baca, M. E., Wells, D. A., Loken, M. R., & Zehentner, B. K. (2011). Detection of genomic abnormalities in multiple myeloma. American Journal of Clinical Pathology, 136(5), 712–720. https://doi.org/10.1309/ajcpf7nflw8uajep
Herrero, A., Rojas, E., Misiewicz-Krzeminska, I., Krzeminski, P., & Gutiérrez, N. (2016). Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma. International Journal of Molecular Sciences, 17(12), 2003. https://doi.org/10.3390/ijms17122003
Huang, S.-Y., Yao, M., Tang, J.-L., Tsay, W., Lee, F.-Y., Liu, M.-C., Wang, C.-H., Chen, Y.-C., Shen, M.-C., &
Tien, H.-F. (2005). Clinical significance of cytogenetics and Interphase Fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Annals of Oncology, 16(9), 1530–1538. https://doi.org/10.1093/annonc/mdi273
Hurt, E. M., Wiestner, A., Rosenwald, A., Shaffer, A. L., Campo, E., Grogan, T., Bergsagel, P. L., Kuehl, W.
M., & Staudt, L. M. (2004). Overexpression of C-MAF is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Cancer Cell, 5(2), 191–199. https://doi.org/10.1016/s1535-6108(04)00019-4
Jiang, Q., Mao, H., He, G., & Mao, X. (2022). Targeting the oncogenic transcription factor C-MAF for the treatment of multiple myeloma. Cancer Letters, 543, 215791.
https://doi.org/10.1016/j.canlet.2022.215791
Jiang, Y., Zhang, C., Lu, L., Wang, X., Liu, H., Jiang, Y., Hong, L., Chen, Y., Huang, H., & Guo, D. (2022).
The prognostic role of Cyclin D1 in multiple myeloma: A systematic review and meta-analysis.
Technology in Cancer Research & Treatment, 21, 153303382110652.
https://doi.org/10.1177/15330338211065252
Kim, K., Lee, J. H., Kim, J. S., Min, C. K., Yoon, S. S., Shimizu, K., Chou, T., Kosugi, H., Suzuki, K., Chen, W., Hou, J., Lu, J., Huang, X.-J., Huang, S.-Y., Chng, W. J., Tan, D., Teoh, G., Chim, C. S., Nawarawong, W., … Durie, B. G. (2014). Clinical profiles of multiple myeloma in Asia-an Asian myeloma network study. American Journal of Hematology, 89(7), 751–756.
https://doi.org/10.1002/ajh.23731
Klimienė, I., Radzevičius, M., Matuzevičienė, R., Sinkevič-Belliot, K., Kučinskienė, Z. A., & Pečeliūnas,
V. (2020). Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
International Journal of Laboratory Hematology, 43(3), 403–408.
https://doi.org/10.1111/ijlh.13387
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017). Multiple myeloma. Nature Reviews Disease Primers, 3(1).
https://doi.org/10.1038/nrdp.2017.46
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V.
(2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 378(3), 241–249. https://doi.org/10.1056/nejmoa1709974
Li, C., Wendlandt, E. B., Darbro, B., Xu, H., Thomas, G. S., Tricot, G., Chen, F., Shaughnessy, J. D., &
Zhan, F. (2021). Genetic analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression. Cancers, 13(3), 517.
https://doi.org/10.3390/cancers13030517
Li, S., Lim, H.-H., Woo, K.-S., Kim, S.-H., & Han, J.-Y. (2016). A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: A single center study in Korea.
Blood Research, 51(2), 122. https://doi.org/10.5045/br.2016.51.2.122
Liehr, T. (2023). Cytogenetics and molecular cytogenetics. CRC Press, Taylor &; Francis Group.
Lim, A. S. T., Lim, T. H., See, K. H. S., Ng, Y. J., Tan, Y. M., Choo, N. S. L., ... & Tan, D. C. L. (2013).
Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in
Singapore. Chinese Medical Journal, 126(10), 1872-1877.
https://10.3760/cma.j.issn.0366-6999.20123344
Lode, L., Eveillard, M., Trichet, V., Soussi, T., Wuilleme, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traulle, C., Guilhot, F., Caillot, D., Marit, G., Mathiot, C., Facon, T., Attal, M.,
exclusively associated with DEL(17P) in multiple myeloma. Haematologica, 95(11), 1973–1976.
https://doi.org/10.3324/haematol.2010.023697
Lu, G., Muddasani, R., Orlowski, R. Z., Abruzzo, L. V., Qazilbash, M. H., You, M. J., Wang, Y., Zhao, M., Chen, S., Glitza, I. C., & Medeiros, L. J. (2013). Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Archives of Pathology & Laboratory Medicine, 137(5), 625–631. https://doi.org/10.5858/arpa.2012-0209-oa
Ludwig, H., Novis Durie, S., Meckl, A., Hinke, A., & Durie, B. (2020). Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. The Oncologist, 25(9).
https://doi.org/10.1634/theoncologist.2020-0141
López-Corral, L., Gutiérrez, N. C., Vidriales, M. B., Mateos, M. V., Rasillo, A., García-Sanz, R., Paiva, B.,
& San Miguel, J. F. (2011). The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clinical Cancer Research, 17(7), 1692–1700. https://doi.org/10.1158/1078-0432.ccr-10-1066
Manier, S., Salem, K., Glavey, S. V., Roccaro, A. M., & Ghobrial, I. M. (2016). Genomic aberrations in
multiple myeloma. Plasma Cell Dyscrasias, 23–34.
https://doi.org/10.1007/978-3-319-40320-5_3
National Comprehensive Cancer Network. (2023). NCCN Guidelines Version 1.2024 Multiple Myeloma. NCCN Clinical Practice Guidelines in Oncology.
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendati ons/GetFileFromFileManagerGuid?FileManagerGuidId=e3395880-f737-42f6-bb45-528c2ec35c dc
OGT. (2021). Haematology fish probes for multiple myeloma. CytoCell.
https://www.ogt.com/media/11of12sf/haematology-fish-probes-for-multiple-myeloma.pdf
Oliva, S., Genuardi, E., Belotti, A., Frascione, P. M., Galli, M., Capra, A., Offidani, M., Vozella, F., Zambello, R., Auclair, D., Kirsch, I., Ruggeri, M., Jacob, A., Ledda, A., Corradini, P., Gilestro, M., Zamagni, E., Musto, P., Boccadoro, M., & Gay, F. (2020). Multiparameter flow cytometry (MFC) and Next Generation Sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the forte trial in newly diagnosed multiple myeloma (mm). Journal of Clinical Oncology, 38(15_suppl), 8533–8533. https://doi.org/10.1200/jco.2020.38.15_suppl.8533
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., Bringhen, S., Gay, F., Attal, M., Passera, R., Spencer, A., Offidani, M., Kumar, S., Musto, P., Lonial, S., … Moreau, P. (2015). Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. Journal of Clinical Oncology, 33(26), 2863–2869. https://doi.org/10.1200/jco.2015.61.2267
Phornsarayuth, P., KorKiasakul, V., Puavilai, T., Boonyawat, K., Niparuck, P., Chuncharunee, S., Chareonsirisuthigul, T., & Rerkamnuaychoke, B. (2016). Molecular cytogenetic aberrations in Thai patients with multiple myeloma. Genomics and Genetics, 9(1).
Pozdnyakova, O., Crowley-Larsen, P., Zota, V., Wang, S. A., & Miron, P. M. (2009). Interphase fish in plasma cell dyscrasia: Increase in abnormality detection with plasma cell enrichment. Cancer
Genetics and Cytogenetics, 189(2), 112–117.
https://doi.org/10.1016/j.cancergencyto.2008.11.007
Rajan, A. M., & Rajkumar, S. V. (2015). Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal, 5(10). https://doi.org/10.1038/bcj.2015.92
Rajkumar, S. V. (2022). Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 97(8), 1086–1107.
https://doi.org/10.1002/ajh.26590
Rasche, L., Kortüm, K., Raab, M., & Weinhold, N. (2019). The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. International Journal of Molecular Sciences, 20(5), 1248. https://doi.org/10.3390/ijms20051248
Sayuti, N. A., Andayani, T. M., Endarti, D., & Taroeno-Hariadi, K. W. (2019). Health- related quality of life for multiple myeloma patients with bone metastases in Indonesia: A cross-sectional study.
Asian Pacific Journal of Cancer Prevention, 20(10), 3161–3166.
https://doi.org/10.31557/apjcp.2019.20.10.3161
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022). Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.973836
Sutandyo, N., Firna, E., Agustina, J., Prayogo, N., & Widjaja, L. (2015). Clinicopathology profile and bone involvement of multiple myeloma patients in Dharmais National Cancer Hospital, Indonesia. Asian Pacific Journal of Cancer Prevention, 16(15), 6261–6265.
https://doi.org/10.7314/apjcp.2015.16.15.6261
Tadjoedin, H., Reksodiputro, A. H., & Toruan, T. (2011). Multiple Myeloma in Indonesia. Indonesian Journal of Cancer, 5(2). https://doi.org/10.33371/ijoc.v5i2.134
Vízkeleti, L., Ecsedi, S., Rákosy, Z., Orosz, A., Lázár, V., Emri, G., Koroknai, V., Kiss, T., Ádány, R., &
Balázs, M. (2012). The role of CCND1 alterations during the progression of cutaneous
malignant melanoma. Tumor Biology, 33(6), 2189–2199.
https://doi.org/10.1007/s13277-012-0480-6
Wiedmeier-Nutor, J. E., & Bergsagel, P. L. (2022). Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. Life, 12(6), 812.
https://doi.org/10.3390/life12060812
Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., & Rao, P. N.
(2007a). Guidance for fluorescence in situ hybridization testing in hematologic disorders. The Journal of Molecular Diagnostics, 9(2), 134–143. https://doi.org/10.2353/jmoldx.2007.060128
Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., & Rao, P. N.
(2007b). Guidance for fluorescence in situ hybridization testing in hematologic disorders. The Journal of Molecular Diagnostics, 9(2), 134–143. https://doi.org/10.2353/jmoldx.2007.060128
Xiong, W., Wu, X., Starnes, S., Johnson, S. K., Haessler, J., Wang, S., Chen, L., Barlogie, B., Shaughnessy, J. D., & Zhan, F. (2008). An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood, 112(10), 4235–4246. https://doi.org/10.1182/blood-2007-10-119123
